NVO Q3 Earnings Call Highlights GLP-1 Growth and Raised Outlook

Novo Nordisk reported Q3 2026 EPS of $0.89 versus $0.81 consensus and revenue of $12.19 billion versus $11.38 billion, a 7.1% positive surprise, and raised its 2026 free-cash-flow outlook to DKK 60–70 billion. Wegovy pill volumes rose about 20% sequentially, but growth relied substantially on Medicare Bridge prescriptions; management expects U.S. sales declines and continued pricing pressure, including 10%–15% annual Ozempic price erosion. CagriSema’s U.S. launch is anticipated in early 2027, subject to regulatory approval, while 2026 adjusted sales and operating-profit growth are forecast at -2% to +2% at constant exchange rates.

Analysis

The key signal is quality, not just quantity, of demand. If incremental oral uptake is disproportionately tied to a temporary access bridge while the underlying category is flat, prescription growth may overstate durable, fully reimbursed revenue. Employer affordability concerns and weaker U.S. net pricing can turn volume gains into limited sales growth—or worse, margin dilution. The near-flat 2026 outlook despite a strong quarter also makes the 2027 setup unusually dependent on execution: launch contribution must outrun semaglutide exclusivity erosion, China weakness, and continued price cuts.

Over the next 1–3 months, the market may reward pill adoption, but the more important evidence is post-bridge persistence and net sales per patient. Over 6–18 months, CagriSema could broaden the portfolio, but trial results alone do not establish regulatory timing, real-world differentiation, payer coverage, or launch economics. The comparison cited against a low tirzepatide dose should not be treated as proof of broad superiority over Eli Lilly’s offering.

Contrarian read: international launch share and prescription share are attention-grabbing but not sufficient evidence of profitable scale; access, persistence, supply, and gross-to-net determine whether they convert. Conversely, a flat headline outlook may understate upside if oral adoption persists without bridge support. No high-conviction directional trade until those economics are observable.

Key Decisions for Investors

• Do not chase the earnings beat on volume headlines alone. Track monthly prescriptions alongside bridge-program exposure, paid-patient mix, persistence, and net realized price; these are the checks on whether demand is durable and monetizable.
• Treat Novo Nordisk as a catalyst-driven, two-sided position over the next quarter rather than a clean growth re-rating. Reassess after the next guidance update or evidence on post-bridge demand; a sustained slowdown in pill starts or weaker net sales per patient would falsify the bullish volume thesis.
• Keep a relative-value watch against Eli Lilly, not an automatic pair trade: consider long Lilly/short Novo Nordisk only if Novo’s oral growth proves access-dependent while its pricing and exclusivity headwinds persist. Reversal trigger: sustained Novo demand after bridge support fades, with improving net sales and credible CagriSema launch execution.
• For a 6–18 month thesis, monitor CagriSema regulatory progress, payer access and launch positioning—not trial weight-loss figures in isolation. Delayed approval, limited coverage, or no evidence of incremental uptake would undermine the prospective offset to erosion.